Novartis shared two-year results for ianalumab, showing better disease activity in Sjögren's disease patients.

Nov 10, 2026, 1:04 PM ETTrialRead the original at marketscreener.com

Good for NVS

The 2-year results show further improvement in disease activity, supporting Novartis' work on ianalumab. It is still being tested, so the report does not show an approved treatment or sales.

NVS · Novartis

AI read · Good for NVS

The AI's read

The findings add support for a possible new treatment in Novartis' research. Further improvement is encouraging. Ianalumab is still being tested, and the report gives no approval or sales results, so its business value is not yet proven.

Get alerts for NVS

Follow Novartis (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVS

Free on the App Store and Google Play, or on the web.